Trial
NCT03287050
Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
—
Condition
Urothelial Carcinoma
Intervention
Pembrolizumab
Why stopped
due to changing therapeutic landscape in metastatic bladder cancer and lack of radiation/immunotherapy systemic synergy in other malignancies
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-15